TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Alliance HealthCare Services to Present at the Deutsche Bank 35th Annual Health Care Conference (Business Wire) NEWPORT BEACH, Calif.----Alliance HealthCare Services, Inc. , a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced that Paul S. Viviano, Chairman of the Board and Chief Executive Officer, and Howard K. us.rd.yahoo.com |
Alliance Healthcare downgraded on imaging, prices (AP) An RBC Capital Markets analyst downgraded shares of Alliance Healthcare Services Inc. Thursday, saying its diagnostic imaging volume will stay low due to the weak economy, and Medicare reimbursement should remain under pressure. us.rd.yahoo.com |
Cancer Vaccines: Northwest Biotherapeutics vs. Dendreon M.E. Garza submits: As a followup to our interview with Northwest Biotherapeutics’ (NWBO.OB) Chairman of the Board of Linda Powers, this article focuses on the “hard differentiators” between NWBO’s immunotherapy vaccine platform and that of their closest competitor Dendreon Corporation (DNDN).Observers and investors of Northwest Biotherapeutics now believe the company’s DCVax may be poised to surpass Dendreon’s product in the field of vaccine based cancer treatments. Speculators have begun to rush back to pick up shares of NWBO just as sector darling Dendreon Corp. has lost 44% of its value after news that Dendreon can only make enough of their recently approved prostate cancer drug to treat about 2% of eligible patients.Complete Story » seekingalpha.com |
What Analysts Won't Tell You About Arena KLLJ Investments submits: Analysts have a job to do, but it isn’t to look out for the retail investor. It is to align expectations with an Investment Bank or Institutions strategy for making money. You will never see an estimate come out of one of the major firms that is on the surface, an audacious prediction. That isn’t to say they don’t forecast aggressive revenue targets internally, but they are for their own consumption and not of a retail investor. Instead, they put out conservative targets and conservative revenue estimates. They come up with negative biases or ‘fear, uncertainty and doubt’ to cap expectations and the share price. They are in this game to make themselves and their wealthy clients’ money, not Joe Investor. That is why you will never see one analyst come out and say what the real value of a Safe and Effective weight loss drug’s potential is. Instead, they will say that weight loss drugs in the past haven’t done well so Arena’s (ARNA) Lorqess will only do a few hundred million dollars instead of pointing out the reasons for current and past weight loss drug failures, which Lorqess has overcome. They’ll come out with FUD (fear, uncertainty and doubt) on how efficacy wasn’t great and use placebo adjusted weight loss figures instead of actual weight loss percentages. They’ll say that 8% weight loss isn’t that meaningful. All of this to keep the share price in check. How wrong they are, and they may even know it. Why do you think Arena’s institutional interest is so high? Even when ARNA was trading at $3 it was high. Do you know how hard it is for institutions to justify investing millions in a $3 stock? Arena underscores the reason why investors have to perform their own extensive due diligence. You can’ t relay on headlines or analyst opinions if you want to make money. Complete Story » seekingalpha.com |
What Medicare Will Ask About Dendreon's Provenge Pharmalot submits: There is yet another twist in the ongoing and always interesting Provenge saga. The Centers for Medicare & Medicaid Services, which last June issued a surprise decision to conduct a National Coverage Analysis, which will be used for coverage guidance by Medicare contractors, has released the questions to be answered at a Nov. 17 panel meeting and the focus is on on-label efficacy. The NCA, for those who may not recall, stunned all sorts of people because such reviews do not occur very often (see here and here). Dendreon (DNDN) execs subsequently downplayed the move by telling analysts NCA was sparked by concerns of off-label use, although CMS has been cryptic about its reasoning other than to point to the fact that Provenge is the first in a new class of treatments that use a patient’s own cells to stimulate the body’s immune system in an approach known as immunotherapy.Complete Story » seekingalpha.com |